Showing results (241-250 of 406) with videos related to
Sort By:
Pageof 41
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemiaFelicitas Thol, Frederik Damm, Andrea Lüdeking, et al.The Lancet. Haematology|March 16, 2019
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trialColin A Hutchison, Paul Cockwell, Veronica Moroz, et al.Hemasphere|September 4, 2023
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi StudyKarthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2010
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patientsSusanne M Rittig, Maik Haentschel, Katrin J Weimer, et al.Annals of Hematology|March 24, 2017
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemiaAnna Both, Jürgen Krauter, Frederik Damm, et al.Blood|June 10, 2010
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyWolfgang A Bethge, Thoralf Lange, Christoph Meisner, et al.Annals of the New York Academy of Sciences|June 12, 2003
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemiaTim H Brummendorf, Inci Ersoz, Ulrike Hartmann, et al.Clinical Lymphoma, Myeloma & Leukemia|July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III TrialKatja Weisel, Meletios Dimopoulos, Kevin W Song, et al.Annals of Hematology|June 16, 2026
Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysisMarie Harzer, Nils Gross-Fengels, Fede Melzer, et al.Pageof 41